These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 35688661)

  • 1. Re: Amar U. Kishan, Xiaoyan Wang, Yilun Sun, et al. High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient-data Network Meta-analysis from the MARCAP Consortium. Eur Urol. 2022;82:106-14.
    Lao Y; Wang Y; Dong Z
    Eur Urol; 2022 Sep; 82(3):e80-e81. PubMed ID: 35688661
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to Yongfeng Lao, Yanan Wang, and Zhilong Dong's Letter to the Editor re: Amar U. Kishan, Xiaoyan Wang, Yilun Sun, et al. High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient-data Network Meta-analysis from the MARCAP Consortium. Eur Urol. 2022;82:106-114.
    Kishan AU; Spratt DE
    Eur Urol; 2022 Sep; 82(3):e82-e83. PubMed ID: 35688665
    [No Abstract]   [Full Text] [Related]  

  • 3. High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient-data Network Meta-analysis from the MARCAP Consortium.
    Kishan AU; Wang X; Sun Y; Romero T; Michalski JM; Ma TM; Feng FY; Sandler HM; Bolla M; Maingon P; De Reijke T; Neven A; Steigler A; Denham JW; Joseph D; Nabid A; Carrier N; Souhami L; Sydes MR; Dearnaley DP; Syndikus I; Tree AC; Incrocci L; Heemsbergen WD; Pos FJ; Zapatero A; Efstathiou JA; Guerrero A; Alvarez A; San-Segundo CG; Maldonado X; Xiang M; Rettig MB; Reiter RE; Zaorsky NG; Ong WL; Dess RT; Steinberg ML; Nickols NG; Roy S; Garcia JA; Spratt DE;
    Eur Urol; 2022 Jul; 82(1):106-114. PubMed ID: 35469702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Re: Liam Bourke, Stephen Gilbert, Richard Hooper, et al. Lifestyle changes for improving disease-specific quality of life in sedentary men on long-term androgen-deprivation therapy for advanced prostate cancer: a randomised controlled trial. Eur Urol 2014;65:865-72; Re: Daniel A. Galvão, Nigel Spry, James Denham, et al. A multicentre year-long randomised controlled trial of exercise training targeting physical functioning in men with prostate cancer previously treated with androgen suppression and radiation from TROG 03.04 RADAR. Eur Urol 2014;65:856-64; Re: Nancy L. Keating, Pang-Hsiang Liu, A. James O'Malley, Stephen J. Freedland, Matthew R. Smith. Androgen-deprivation therapy and diabetes control among diabetic men with prostate cancer. Eur Urol 2014;65:816-24; Re: Christina G. Jespersen, Mette Nørgaard, Michael Borre. Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study. Eur Urol 2014;65:704-9.
    Goonewardene SS; Persad R; Young A; Makar A
    Eur Urol; 2014 Sep; 66(3):e51-2. PubMed ID: 24813269
    [No Abstract]   [Full Text] [Related]  

  • 5. Re: Bo Dai, Sheng Zhang, Fan-Ning Wan, et al. Combination of Androgen Deprivation Therapy with Radical Local Therapy Versus Androgen Deprivation Therapy Alone for Newly Diagnosed Oligometastatic Prostate Cancer : A Phase 2 Randomized Controlled Trial. Eur Urol Oncol 2022;5:519-25.
    Montorsi F; Barletta F; Gandaglia G
    Eur Urol Oncol; 2023 Aug; 6(4):451. PubMed ID: 36707322
    [No Abstract]   [Full Text] [Related]  

  • 6. Reply to Leonard P. Bokhorst and Berdine L. Heesterman's Words of Wisdom re: High-dose Radiotherapy and Risk-adapted Androgen Deprivation in Localised Prostate Cancer (DART 01/05): 10-Year Results of a Phase 3 Randomised, Controlled Trial. Eur Urol. 2022;82:441.
    Zapatero A; Calvo FA; Gonzalez San-Segundo C; Alvarez A
    Eur Urol; 2022 Dec; 82(6):e177-e178. PubMed ID: 36115773
    [No Abstract]   [Full Text] [Related]  

  • 7. Re: Rhonda L. Bitting, Patrick Healy, Daniel J. George, et al. Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM Trial. Eur Urol Oncol 2021;4:948-54.
    Guler OC; Isci O; Onal C
    Eur Urol Oncol; 2022 Aug; 5(4):477-478. PubMed ID: 35307322
    [No Abstract]   [Full Text] [Related]  

  • 8. Re: Amar U. Kishan, Talha Shaikh, Pin-Chieh Wang, et al. Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis. Eur Urol 2017;71:766-73.
    Van den Broeck T; Karnes RJ; Joniau S
    Eur Urol; 2017 Nov; 72(5):e121-e122. PubMed ID: 28108149
    [No Abstract]   [Full Text] [Related]  

  • 9. Re: Soumyajit Roy, Yilun Sun, Scott C. Morgan, et al. Effect of Prior Local Therapy on Response to First-line Androgen Receptor Axis Targeted Therapy in Metastatic Castrate-resistant Prostate Cancer: A Secondary Analysis of the COU-AA-302 Trial. Eur Urol 2023;83:571-9.
    Li X; Xu Z; Qi F
    Eur Urol; 2024 Jan; 85(1):e14. PubMed ID: 37596190
    [No Abstract]   [Full Text] [Related]  

  • 10. Re: Urs E. Studer, Laurence Collette, Peter Whelan, et al. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). Eur Urol 2008;53:941-9 and re: John Anderson. Androgen-deprivation therapy--It's all a matter of timing. Eur Urol 2008;53:869-71.
    Kirollos MM
    Eur Urol; 2009 Feb; 55(2):e40-2; author reply e45-6. PubMed ID: 18760526
    [No Abstract]   [Full Text] [Related]  

  • 11. Re: Vincenzo Pagliarulo, Sergio Bracarda, Mario A. Eisenberger, et al. Contemporary role of androgen deprivation therapy for prostate cancer. Eur Urol 2012;61:11–25.
    Cornel EB
    Eur Urol; 2012 Jun; 61(6):e59; author reply e60. PubMed ID: 22386192
    [No Abstract]   [Full Text] [Related]  

  • 12. Reply to Xiao Li, Zicheng Xu, and Feng Qi's Letter to the Editor re: Soumyajit Roy, Yilun Sun, Scott C. Morgan, et al. Effect of Prior Local Therapy on Response to First-line Androgen Receptor Axis Targeted Therapy in Metastatic Castrate-resistant Prostate Cancer: A Secondary Analysis of the COU-AA-302 Trial. Eur Urol 2023;83:571-9.
    Roy S; Sun Y; Morgan S; Malone S
    Eur Urol; 2024 Jan; 85(1):e12-e13. PubMed ID: 37596192
    [No Abstract]   [Full Text] [Related]  

  • 13. Re: Loren K. Mell, Stephanie L. Pugh, Christopher U. Jones, et al. Effects of Androgen Deprivation Therapy on Prostate Cancer Outcomes According to Competing Event Risk: Secondary Analysis of a Phase 3 Randomised Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.01.020.
    Jung J; Kim JH
    Eur Urol; 2023 Sep; 84(3):e73-e74. PubMed ID: 37202316
    [No Abstract]   [Full Text] [Related]  

  • 14. Reply to Thomas Van den Broeck, R. Jeffrey Karnes, and Steven Joniau's Letter to the Editor re: Amar U. Kishan, Talha Shaikh, Pin-Chieh Wang, et al. Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis. Eur Urol 2017;71:766-73.
    Kishan AU; Steinberg ML; Kupelian PA; King CR
    Eur Urol; 2017 Nov; 72(5):e123-e124. PubMed ID: 28111115
    [No Abstract]   [Full Text] [Related]  

  • 15. Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis.
    Kishan AU; Sun Y; Hartman H; Pisansky TM; Bolla M; Neven A; Steigler A; Denham JW; Feng FY; Zapatero A; Armstrong JG; Nabid A; Carrier N; Souhami L; Dunne MT; Efstathiou JA; Sandler HM; Guerrero A; Joseph D; Maingon P; de Reijke TM; Maldonado X; Ma TM; Romero T; Wang X; Rettig MB; Reiter RE; Zaorsky NG; Steinberg ML; Nickols NG; Jia AY; Garcia JA; Spratt DE;
    Lancet Oncol; 2022 Feb; 23(2):304-316. PubMed ID: 35051385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Re: Claude C. Schulman, Jacques Irani, Juan Morote, et al. Androgen-deprivation therapy in prostate cancer: a European expert panel review. Eur Urol suppl 2010;9:675-91.
    Langley RE; Price P; Abel PD
    Eur Urol; 2011 Apr; 59(4):e24-5; author reply e26. PubMed ID: 21255905
    [No Abstract]   [Full Text] [Related]  

  • 17. Re: Amar U. Kishan, Rahul D. Tendulkar, Phuoc T. Tran, et al. Optimizing the Timing of Salvage Postprostatectomy Radiotherapy and the Use of Concurrent Hormonal Therapy for Prostate Adenocarcinoma. Eur Urol Oncol. In press: Primum Non Nocere: Adding Hormone Therapy to Early Salvage Radiotherapy Makes the Physician Feel Better, But Does It Help the Patient?
    Spratt DE; Feng FY
    Eur Urol Oncol; 2018 Sep; 1(4):323-324. PubMed ID: 31100255
    [No Abstract]   [Full Text] [Related]  

  • 18. Role of Androgen-Deprivation Therapy Remains Uncertain for Intermediate-Risk Patients When Using Dose-Escalated Radiotherapy.
    Kollmeier MA; McBride S; Gorovets D; Zelefsky MJ
    J Clin Oncol; 2020 Nov; 38(32):3821-3822. PubMed ID: 32997577
    [No Abstract]   [Full Text] [Related]  

  • 19. Re: Urs E. Studer, Laurence Collette, Peter Whelan, et al. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). Eur Urol 2008;53:941-9.
    Ragavan N; Singh PB; Martin FL; Baird AD
    Eur Urol; 2009 Feb; 55(2):e43-4. PubMed ID: 18771846
    [No Abstract]   [Full Text] [Related]  

  • 20. Reply from Authors re: Ronald C. Chen. Decisions Regarding Whether to Use Androgen Deprivation Therapy with Radiotherapy in Prostate Cancer: Is Cardiovascular Mortality the Most Relevant Outcome? Eur Urol 2016;69:211-2: Outcomes for Favorable and Unfavorable Intermediate Risk Prostate Cancer Patients Receiving Radiation Therapy With or Without Short-term Androgen Deprivation Therapy.
    Voog JC; Paulus R; Efstathiou JA
    Eur Urol; 2016 Feb; 69(2):212-3. PubMed ID: 26443430
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.